Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04459416
PHASE3

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by relieving pain. Researchers also want to find out more about the effects of acupuncture treatments on other symptoms caused by cancer treatments and quality of life.

Official title: Opioid-Sparing Pain Treatment In Myeloma And Lymphoma Patients Undergoing High-Dose Chemotherapy (OPTIMAL-HiChemo): Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

299

Start Date

2020-06-30

Completion Date

2026-06

Last Updated

2025-10-20

Healthy Volunteers

No

Interventions

OTHER

Acupuncture

Acupuncture treatments will be scheduled to cover the period of high symptom burden. Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. Electrical stimulation (e-acupuncture) may be applied to the ST36 and SP6 points when appropriate as per standard acupuncture practice.

DRUG

opioid

All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.

OTHER

Assessments

Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.

Locations (3)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Seattle Cancel Care Alliance (Data Collection Only)

Seattle, Washington, United States